JP2006517976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517976A5 JP2006517976A5 JP2006503591A JP2006503591A JP2006517976A5 JP 2006517976 A5 JP2006517976 A5 JP 2006517976A5 JP 2006503591 A JP2006503591 A JP 2006503591A JP 2006503591 A JP2006503591 A JP 2006503591A JP 2006517976 A5 JP2006517976 A5 JP 2006517976A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- substituted
- optionally substituted
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 152
- 150000001875 compounds Chemical class 0.000 claims 71
- 125000001072 heteroaryl group Chemical group 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 46
- 239000001257 hydrogen Substances 0.000 claims 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 45
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 150000002431 hydrogen Chemical class 0.000 claims 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 13
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 206010040070 Septic Shock Diseases 0.000 claims 9
- 206010003246 arthritis Diseases 0.000 claims 9
- 125000003107 substituted aryl group Chemical group 0.000 claims 9
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 claims 7
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 6
- 206010035664 Pneumonia Diseases 0.000 claims 6
- 206010040047 Sepsis Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- -1 —C (O) Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010063094 Cerebral malaria Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000018652 Closed Head injury Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 206010014824 Endotoxic shock Diseases 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 201000005569 Gout Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 201000009906 Meningitis Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 208000033464 Reiter syndrome Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 201000010001 Silicosis Diseases 0.000 claims 3
- 206010042496 Sunburn Diseases 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 3
- 206010048873 Traumatic arthritis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 208000019664 bone resorption disease Diseases 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 3
- 210000000078 claw Anatomy 0.000 claims 3
- 208000010247 contact dermatitis Diseases 0.000 claims 3
- 210000004351 coronary vessel Anatomy 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 210000002216 heart Anatomy 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 3
- 208000002574 reactive arthritis Diseases 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 201000005404 rubella Diseases 0.000 claims 3
- 230000036303 septic shock Effects 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 201000004595 synovitis Diseases 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- 230000003519 ventilatory effect Effects 0.000 claims 3
- PYQCKLNGCQVGFP-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1,3-dihydroxypropan-2-ylamino)-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(NC(CO)CO)=CC=2N1C1=CC=CC=C1Cl PYQCKLNGCQVGFP-UHFFFAOYSA-N 0.000 claims 2
- AHUOKSBJVXQBQH-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1,3-dihydroxypropan-2-ylamino)quinolin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=CC(NC(CO)CO)=CC=1C1=CC=CC=C1Cl AHUOKSBJVXQBQH-UHFFFAOYSA-N 0.000 claims 2
- RBYQNKUAGUQDAA-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1h-imidazol-2-ylmethylamino)-1,6-naphthyridin-2-one Chemical compound ClC1=CC=CC=C1C1=NC(NCC=2NC=CN=2)=CC2=C1C=CC(=O)N2C1=CC=CC=C1Cl RBYQNKUAGUQDAA-UHFFFAOYSA-N 0.000 claims 2
- UTEMMEATFDOJTF-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-[2-(propan-2-ylamino)ethylamino]-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(NCCNC(C)C)=CC=2N1C1=CC=CC=C1Cl UTEMMEATFDOJTF-UHFFFAOYSA-N 0.000 claims 2
- WLVWEQBXJOIHES-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-[2-(propan-2-ylamino)ethylamino]quinolin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=CC(NCCNC(C)C)=CC=1C1=CC=CC=C1Cl WLVWEQBXJOIHES-UHFFFAOYSA-N 0.000 claims 2
- GMZQTGQJWIBEEA-UHFFFAOYSA-N 1,5-bis(4-fluorophenyl)-1,8-naphthyridin-2-one Chemical compound C1=CC(F)=CC=C1C1=CC=NC2=C1C=CC(=O)N2C1=CC=C(F)C=C1 GMZQTGQJWIBEEA-UHFFFAOYSA-N 0.000 claims 2
- FGRCFQSRHJPOOF-UHFFFAOYSA-N 1,5-bis(4-fluorophenyl)quinolin-2-one Chemical compound C1=CC(F)=CC=C1C1=CC=CC2=C1C=CC(=O)N2C1=CC=C(F)C=C1 FGRCFQSRHJPOOF-UHFFFAOYSA-N 0.000 claims 2
- NCVGTRDMXZGULL-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylphenyl)quinolin-2-one Chemical compound C1=CC(C)=CC=C1C1=CC=CC2=C1C=CC(=O)N2C1=CC=C(F)C=C1 NCVGTRDMXZGULL-UHFFFAOYSA-N 0.000 claims 2
- YGRYGQKVGGEPER-UHFFFAOYSA-N 5-(2,4-difluorophenyl)-1-(4-fluorophenyl)-1,8-naphthyridin-2-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C(C=3C(=CC(F)=CC=3)F)C=CN=C21 YGRYGQKVGGEPER-UHFFFAOYSA-N 0.000 claims 2
- LIYRXUGPUPJBLG-UHFFFAOYSA-N 5-(2,4-difluorophenyl)-1-(4-fluorophenyl)quinolin-2-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C(C=3C(=CC(F)=CC=3)F)C=CC=C21 LIYRXUGPUPJBLG-UHFFFAOYSA-N 0.000 claims 2
- WGRXIIODSLLFHX-UHFFFAOYSA-N 5-(2-fluorophenyl)-1-(4-fluorophenyl)quinolin-2-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C(C=3C(=CC=CC=3)F)C=CC=C21 WGRXIIODSLLFHX-UHFFFAOYSA-N 0.000 claims 2
- OZRPUNDRYYIJFC-UHFFFAOYSA-N 6-bromo-1,5-bis(2-chlorophenyl)-7-methoxyquinolin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=C(Br)C(OC)=CC=2N1C1=CC=CC=C1Cl OZRPUNDRYYIJFC-UHFFFAOYSA-N 0.000 claims 2
- IGZZQGLWJPZOIX-UHFFFAOYSA-N 7-amino-1,5-bis(2-chlorophenyl)-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(N)=CC=2N1C1=CC=CC=C1Cl IGZZQGLWJPZOIX-UHFFFAOYSA-N 0.000 claims 2
- AHCYGXRBOJTSOA-UHFFFAOYSA-N 7-bromo-1,5-bis(2-chlorophenyl)-1,6-naphthyridin-2-one Chemical compound ClC1=CC=CC=C1C1=NC(Br)=CC2=C1C=CC(=O)N2C1=CC=CC=C1Cl AHCYGXRBOJTSOA-UHFFFAOYSA-N 0.000 claims 2
- CNFITDNLXNAZHQ-UHFFFAOYSA-N 7-bromo-1,5-bis(2-chlorophenyl)-3,4-dihydro-1,6-naphthyridin-2-one Chemical compound ClC1=CC=CC=C1N1C(C=C(Br)N=C2C=3C(=CC=CC=3)Cl)=C2CCC1=O CNFITDNLXNAZHQ-UHFFFAOYSA-N 0.000 claims 2
- HYXWKBBZPPNFRK-UHFFFAOYSA-N 7-chloro-1,5-bis(2-chlorophenyl)-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(Cl)=CC=2N1C1=CC=CC=C1Cl HYXWKBBZPPNFRK-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- IURAJLZDFDIJDK-UHFFFAOYSA-N n-[2-[[1,5-bis(2-chlorophenyl)-2-oxo-1,6-naphthyridin-7-yl]amino]ethyl]acetamide Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(NCCNC(=O)C)=CC=2N1C1=CC=CC=C1Cl IURAJLZDFDIJDK-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- GMGXDNHBKGSSGN-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1,3-dihydroxypropan-2-ylamino)-1,8-naphthyridin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=NC(NC(CO)CO)=CC=1C1=CC=CC=C1Cl GMGXDNHBKGSSGN-UHFFFAOYSA-N 0.000 claims 1
- LNDRWHWANLOMIC-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-[2-(propan-2-ylamino)ethylamino]-1,8-naphthyridin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=NC(NCCNC(C)C)=CC=1C1=CC=CC=C1Cl LNDRWHWANLOMIC-UHFFFAOYSA-N 0.000 claims 1
- RKISHQNZYVTTPG-UHFFFAOYSA-N 1,5-diphenyl-1,6-naphthyridin-2-one Chemical compound O=C1C=CC2=C(C=3C=CC=CC=3)N=CC=C2N1C1=CC=CC=C1 RKISHQNZYVTTPG-UHFFFAOYSA-N 0.000 claims 1
- PNBNHPIRIQEGTR-UHFFFAOYSA-N 1-benzyl-5-phenyl-1,6-naphthyridin-2-one Chemical compound O=C1C=CC2=C(C=3C=CC=CC=3)N=CC=C2N1CC1=CC=CC=C1 PNBNHPIRIQEGTR-UHFFFAOYSA-N 0.000 claims 1
- PIOGKVWSMAZIFA-UHFFFAOYSA-N 1-methyl-5-phenyl-1,6-naphthyridin-2-one Chemical compound C=12C=CC(=O)N(C)C2=CC=NC=1C1=CC=CC=C1 PIOGKVWSMAZIFA-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- APKKZTGSYROVPP-UHFFFAOYSA-N 5-phenyl-1h-1,6-naphthyridin-2-one Chemical compound N1=CC=C2NC(=O)C=CC2=C1C1=CC=CC=C1 APKKZTGSYROVPP-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44741003P | 2003-02-14 | 2003-02-14 | |
| US53809504P | 2004-01-21 | 2004-01-21 | |
| PCT/US2004/004406 WO2004073628A2 (en) | 2003-02-14 | 2004-02-13 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517976A JP2006517976A (ja) | 2006-08-03 |
| JP2006517976A5 true JP2006517976A5 (https=) | 2008-10-09 |
Family
ID=32912260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503591A Pending JP2006517976A (ja) | 2003-02-14 | 2004-02-13 | 新規化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7550480B2 (https=) |
| EP (1) | EP1596860A4 (https=) |
| JP (1) | JP2006517976A (https=) |
| AU (1) | AU2004212957A1 (https=) |
| CA (1) | CA2515939A1 (https=) |
| MX (1) | MXPA05008612A (https=) |
| PL (1) | PL378111A1 (https=) |
| WO (1) | WO2004073628A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20061193A1 (es) | 2005-03-25 | 2006-12-02 | Glaxo Group Ltd | DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38 |
| MY145343A (en) | 2005-03-25 | 2012-01-31 | Glaxo Group Ltd | Novel compounds |
| ES2600460T3 (es) * | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
| WO2008001929A1 (en) | 2006-06-28 | 2008-01-03 | Aska Pharmaceutical Co., Ltd. | Treatment agent for inflammatory bowel disease |
| AU2008215659B2 (en) | 2007-02-16 | 2012-11-01 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| MX2010013842A (es) * | 2008-07-03 | 2011-01-14 | Merck Patent Gmbh | Naftiridinonas como inhibidores de aurora cinasa. |
| CN103034654B (zh) * | 2011-10-10 | 2016-06-15 | 中国电信股份有限公司 | 社会化动态消息呈现控制方法及系统 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| JP6529085B2 (ja) * | 2014-04-18 | 2019-06-12 | 武田薬品工業株式会社 | 複素環化合物 |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| JP2024504285A (ja) * | 2020-12-29 | 2024-01-31 | ティーエックスイノ バイオサイエンス インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼの阻害活性を有する新規のナフチリジノン誘導体及びこれらの用途 |
| CN116669726A (zh) * | 2020-12-29 | 2023-08-29 | 谛希诺生物科技有限公司 | 对外核苷酸焦磷酸酶-磷酸二酯酶具有抑制活性的新颖的萘啶酮衍生物及其用途 |
| JP7624093B2 (ja) * | 2022-04-08 | 2025-01-29 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA966134A (en) * | 1972-05-05 | 1975-04-15 | Haydn W.R. Williams | 1,8-naphthyridine compounds |
| US3962262A (en) * | 1973-04-11 | 1976-06-08 | Merck & Co., Inc. | 1,8-naphthyridine compounds |
| US4031103A (en) * | 1974-06-07 | 1977-06-21 | Merck Sharp & Dohme (I.A.) Corporation | 1,8-Naphthyridine compounds |
| ZA803539B (en) * | 1979-06-14 | 1982-01-27 | Wellcome Found | Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine |
| US4710507A (en) * | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
| US4560691A (en) | 1984-07-13 | 1985-12-24 | Sterling Drug Inc. | 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation |
| US4567186A (en) * | 1985-01-14 | 1986-01-28 | Sterling Drug Inc. | 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor |
| US4650806A (en) * | 1985-01-14 | 1987-03-17 | Sterling Drug Inc. | Cardiotonic 5-(heterylcarbonyl)-pyridones |
| NZ214837A (en) * | 1985-01-28 | 1988-10-28 | Sterling Drug Inc | 5-substituted 1,6 naphthyridin-2(1h)-ones |
| EP0278686A1 (en) | 1987-02-07 | 1988-08-17 | The Wellcome Foundation Limited | Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof |
| JPH01261306A (ja) | 1988-04-13 | 1989-10-18 | Nippon Kayaku Co Ltd | ２−アルキルチオ−４−アミノピリミジン誘導体を有効成分とする開花促進剤 |
| DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
| SG64322A1 (en) * | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| DE4131029A1 (de) * | 1991-09-18 | 1993-07-29 | Basf Ag | Substituierte pyrido (2,3-d) pyrimidine als antidots |
| US5426110A (en) * | 1993-10-06 | 1995-06-20 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
| US5547954A (en) * | 1994-05-26 | 1996-08-20 | Fmc Corporation | 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides |
| WO1996006843A1 (en) * | 1994-08-29 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Novel naphthyridine derivative and medicinal composition thereof |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6875769B2 (en) * | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
| US5989588A (en) * | 1996-10-04 | 1999-11-23 | Merck & Co., Inc. | Methods and compositions for preventing and treating heartburn |
| US5945422A (en) * | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| EA200000840A1 (ru) * | 1998-02-17 | 2001-02-26 | Туларик, Инк. | Антивирусные производные пиримидина |
| AP2002002651A0 (en) * | 2000-04-28 | 2002-12-31 | Pfizer Prod Inc | Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| JP2004521892A (ja) * | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 |
| JP4178783B2 (ja) | 2001-10-19 | 2008-11-12 | 三菱化学株式会社 | 光学記録媒体 |
-
2004
- 2004-02-13 US US10/545,565 patent/US7550480B2/en not_active Expired - Fee Related
- 2004-02-13 MX MXPA05008612A patent/MXPA05008612A/es unknown
- 2004-02-13 EP EP04711237A patent/EP1596860A4/en not_active Withdrawn
- 2004-02-13 WO PCT/US2004/004406 patent/WO2004073628A2/en not_active Ceased
- 2004-02-13 JP JP2006503591A patent/JP2006517976A/ja active Pending
- 2004-02-13 AU AU2004212957A patent/AU2004212957A1/en not_active Abandoned
- 2004-02-13 CA CA002515939A patent/CA2515939A1/en not_active Abandoned
- 2004-02-13 PL PL378111A patent/PL378111A1/pl not_active Application Discontinuation
-
2009
- 2009-05-15 US US12/466,401 patent/US20090239897A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517976A5 (https=) | ||
| CA2328780C (en) | Dihydropyrimidines | |
| AU2013307328B2 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| US6245770B1 (en) | Fungicidal pyrimidinones | |
| AU2016417542B2 (en) | Imidazopyridine thioglycolic acid derivative, preparation method therefor and application thereof | |
| JP2003525295A5 (https=) | ||
| KR102346508B1 (ko) | 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물 | |
| EP3013815B1 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| JP2013504593A5 (https=) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| NZ259114A (en) | Pyrazolopyrimidines and pharmaceutical compositions thereof | |
| CZ20022390A3 (cs) | Antagonisty faktoru uvolňujícího kortikotropin | |
| KR20120120271A (ko) | 치환된 이미다조피리디닐-아미노피리딘 화합물 | |
| KR20120124428A (ko) | 치환된 피롤로-아미노피리미딘 화합물 | |
| JP2017512786A5 (https=) | ||
| JP2016540803A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2020500869A5 (https=) | ||
| JP2005530811A5 (https=) | ||
| JP2018526419A5 (https=) | ||
| JP2006508979A5 (https=) | ||
| TW200911802A (en) | 7-alkynyl-1,8-naphthyridone derivatives, preparation thereof and therapeutic use thereof | |
| JP2008509955A5 (https=) | ||
| RU2004133811A (ru) | Новые соединения | |
| CN112409293A (zh) | 苯并噻嗪酮化合物及其制备方法与作为抗结核药物的应用 |